VF arrest secondary to immune checkpoint inhibitor (ICI)-associated myocarditis; improving patient outcomes by maintaining a high clinical suspicion for ICI toxicity
Introduction: Use of immune checkpoint inhibitor (ICI) medications has revolutionised clinical outcomes and remains an exciting prospect in oncology as further indications are revealed.1 However, adverse effects, or toxicities, secondary to their non-targeted immunological activation create an array...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Clinical Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1470211825002015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!